How many biosimilars have been approved in the United States?
What are the biosimilars for Avastin, Enbrel, Epogen, Herceptin, Humira, Neulasta, Neupogen, Remicade, and Rituxan? ·
Medically reviewed by J. Stewart, BPharm. Last updated on Apr 25, 2019.
Official Answerby Drugs.com
The number of biosimilars currently approved by the FDA is nineteen.
The most recent approval was Eticovo (etanercept-ykro) on April 25, 2019.
What is a biosimilar?
According the to FDA, a biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.
Avastin (bevacizumab) Biosimilars
- Mvasi (bevacizumab-awwb)
Enbrel (etanercept) Biosimilars
Epogen / Procrit (epoetin alfa) Biosimilars
- Retacrit (epoetin alfa-epbx)
Herceptin (trastuzumab) Biosimilars
- Ogivri (trastuzumab-dkst)
- Herzuma (trastuzumab-pkrb)
- Ontruzant (trastuzumab-dttb)
- Trazimera (trastuzumab-qyyp)
Humira (adalimumab) Biosimilars
Neulasta (pegfilgrastim) Biosimilars
Neupogen (filgrastim) Biosimilars
Remicade (infliximab) Biosimilars
Rituxan (rituximab) Biosimilars
- Truxima (rituximab-abbs)
More information: What Are Biosimilars? Top Facts You May Not Know